Eli Lilly & Co. has started a Phase 3 trial of its experimental antibody-based COVID-19 drug in nursing homes and other long-term care facilities, testing whether the drug reduces the infection rate at facilities where residents or staff have recently tested positive for the new coronavirus. The study involves Eli Lilly driving specially modified RVs to newly infected nursing homes and injecting its COVID-19 drug, code-named LY-CoV555, in volunteers, The Wall Street Journal reports. The company said its drug may get government approval by the end of 2020.
Eli Lilly is already testing its antibody treatment, developed with Canadian biotech AbCellera Biologics, in hospitals on COVID-19 patents with mild and more severe cases. Researchers essentially cloned antibodies from one of the first U.S. patients to recover from COVID-19, hoping those proteins help the immune system fight the virus or prevent it from taking hold. If Eli Lilly's drug or another like it proves safe and effective, public health experts say it might serve as a bridge until a vaccine is available.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
-
Do smartphone bans in schools work?The Explainer Trials in UK, New Zealand, France and the US found prohibition may be only part of the solution
-
Doom: The Dark Ages – an 'exhilarating' prequelThe Week Recommends Legendary shooter adds new combat options from timed parries to melee attacks and a 'particularly satisfying' shield charge
-
7 US cities to explore on a microtripThe Week Recommends Not enough vacation days? No problem.
-
Warren Buffet announces surprise retirementspeed read At the annual meeting of Berkshire Hathaway, the billionaire investor named Vice Chairman Greg Abel his replacement
-
Trump calls Amazon's Bezos over tariff displaySpeed Read The president was not happy with reports that Amazon would list the added cost from tariffs alongside product prices
-
Markets notch worst quarter in years as new tariffs loomSpeed Read The S&P 500 is on track for its worst month since 2022 as investors brace for Trump's tariffs
-
Tesla Cybertrucks recalled over dislodging panelsSpeed Read Almost every Cybertruck in the US has been recalled over a stainless steel panel that could fall off
-
Crafting emporium Joann is going out of businessSpeed Read The 82-year-old fabric and crafts store will be closing all 800 of its stores
-
Trump's China tariffs start after Canada, Mexico pausesSpeed Read The president paused his tariffs on America's closest neighbors after speaking to their leaders, but his import tax on Chinese goods has taken effect
-
Chinese AI chatbot's rise slams US tech stocksSpeed Read The sudden popularity of a new AI chatbot from Chinese startup DeepSeek has sent U.S. tech stocks tumbling
-
US port strike averted with tentative labor dealSpeed Read The strike could have shut down major ports from Texas to Maine
